Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson.

D L Barnard1

  • 1Utah State University, Institute for Antiviral Research, 5600 Old Main Hill, Logan, UT 84322-5600, USA. honery@cc.usu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary

RWJ-270201, an influenza neuraminidase inhibitor, demonstrated significant viral titer reduction in patients. This investigational drug, developed by BioCryst, is well-tolerated and shows promise for influenza treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro and in vivo influenza virus-inhibitory effects of viramidine.

Antiviral research·2005
Same author

Antiviral research - 13th International Conference.

IDrugs : the investigational drugs journal·2005
Same author

Antiviral Research - 15th International Conference. Mega-HAART and tenofovir. 17-21 March 2002, Prague, Czech Republic.

IDrugs : the investigational drugs journal·2004
Same author

In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.

Antimicrobial agents and chemotherapy·2004
Same author

Fulminant Crohn's colitis after allogeneic stem cell transplantation.

Gut·2003
Same author

Pulmonary complications following bone marrow transplantation.

The British journal of radiology·2003

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Influenza remains a significant global health concern, necessitating the development of novel antiviral therapies.
  • Neuraminidase inhibitors are a key class of antiviral drugs targeting influenza virus replication.
  • RWJ-270201 is a novel compound identified as a potent inhibitor of influenza neuraminidase.

Purpose of the Study:

  • To evaluate the efficacy of RWJ-270201 in reducing viral load in influenza-infected patients.
  • To assess the safety and tolerability profile of RWJ-270201 during clinical trials.
  • To determine the potential of RWJ-270201 as a therapeutic agent for influenza.

Main Methods:

  • Phase II clinical studies were conducted to assess RWJ-270201's effectiveness.
  • Viral titers in infected patients were measured to quantify antiviral activity.
  • Patient tolerance and adverse events were monitored throughout the study.

Main Results:

  • RWJ-270201 demonstrated statistically significant reductions in viral titers.
  • The compound was found to be well-tolerated by patients in Phase II studies.
  • Phase III trials were initiated in North America and Europe.

Conclusions:

  • RWJ-270201 exhibits promising antiviral activity against influenza.
  • The drug's favorable tolerability supports its continued development for influenza treatment.
  • Further clinical evaluation is warranted to establish its therapeutic role.

Related Experiment Videos